MSC-EVs from healthy individuals inhibit the MM cell proliferation in vitro, though their counterparts from MM patients have the opposite effect by activating the AKT pathway and inhibiting the p38, p53, and c-Jun N-terminal kinase (JNK) pathway [76,77,78,79]. This evidence concerns the gene TP53 and Miyoshi myopathy.